Akanda Corp. (AKAN) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Akanda Corp (AKAN) 3-Minute Overview ### 🎯 Layer 1: 30-Second Key Takeaways > **💡 One-Sentence Summary** > > Simply put, Akanda is a tiny, highly speculative NASDAQ-listed company tied to the pharmaceuticals space, but right now the stock looks driven more by trading volatility and corporate actions than by proven operating strength. > **📍 Basic Profile** > > Market Cap **$0.01 billion** · Pharmaceuticals · NASDAQ NMS - GLOBAL MARKET · Price **$10.21** > **⚡ 3 Things You Should Know** > > 1. ⚠️ **This is a micro-cap trading vehicle right now:** The stock jumped more than 200% in a day and triggered multiple circuit-breaker halts, which usually tells you price action is being driven by momentum and low float dynamics rather than fundamentals. > > 2. 📉 **The business is still deeply unprofitable:** Gross margin is only 29.1%, while net margin is an extreme **-516.0%**, so even if revenue has grown fast off a small base, the company is nowhere near showing a durable earnings model. > > 3. 🔄 **Reverse split is a yellow flag, not a growth catalyst:** The announced 1-for-4.5 reverse stock split may help with listing optics, but in small caps it often signals pressure to maintain exchange compliance rather than underlying business improvement. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Weak👎 | Net margin -516.03%, deeply loss-making | > | Growth Rate | Fast🚀 | Revenue growth 172.38% over 3 years, but likely from a small base | > | Financial Health | Moderate💛 | Debt/equity 8.25%, but liquidity is only somewhat above 1x | > | Valuation | [Data unavailable] | PE unavailable; P/S 1.32x, P/B 0.41x | --- ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** [Data partially unavailable] Akanda appears to operate around pharmaceutical-related activities, making money by selling its products/services through its operating subsidiaries, but the provided data does not clearly break out its exact revenue sources. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Pharmaceuticals-related operations | [Data unavailable] | ↑ | Revenue has grown sharply over 3 years, but segment detail is missing | | Subsidiary infrastructure/fiber activity | [Data unavailable] | ↑ | Recent news suggests a non-core-looking revenue addition, which raises questions about business focus | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | 29.1% | Below Average | It keeps some gross profit, but not enough to absorb overhead | | Net Margin | -516.03% | Below Average | Losing far more than it sells; economics are currently very weak | | ROE | -153.25% | Average | Negative ROE this large usually means shareholder capital is being eroded | --- #### 📈 How's the Growth? **Growth Assessment:** High Growth | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Quality:** > What's important here is that the reported 3-year revenue growth of 172.38% sounds exciting, but without yearly revenue figures or segment disclosure, it's hard to know whether this is healthy operating expansion or just growth off a very tiny starting base. In other words, the top line may be rising, but the huge losses suggest that growth has not translated into business quality yet. --- #### 💰 Financial Health Check **One Sentence:** Think of it like a person with little long-term debt, but unstable income and ongoing cash burn—so not overleveraged, but still financially fragile. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | 8.25% | <60% safe | ✅Safe | | Current Ratio | 1.25 | >1.5 healthy | ⚠️Tight | | Cash Flow | -$0.19/share | >0 | 🚨Negative | --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $2.29 - 52-Week High: $209.03 - Current: $10.21, Near the low | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | ●(3.8% position) | | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE [Data unavailable] | 5-year avg [Data unavailable] | [Data unavailable] | | vs Peers | PE [Data unavailable] | Industry avg [Data unavailable] | [Data unavailable] | **What the Current Valuation is Betting On:** > Basically, the low P/B of 0.41x and low position in the 52-week range suggest the market has little faith in the current business model. At the same time, the sudden spike in price suggests traders are betting more on squeezes, restructuring optics, or speculative momentum than on a clean earnings turnaround. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-04-08 | Akanda announced a 1-for-4.5 reverse stock split effective April 13, 2026 | Negative/Neutral — helps listing mechanics, but often reflects stress in small-cap stocks | | 2026-04-21 | Shares were repeatedly halted on circuit breakers during a massive intraday move | Neutral/Negative — strong momentum for traders, but a warning sign for long-term investors about extreme volatility | | 2026-03-25 | Subsidiary First Towers & Fiber added 200km of fiber coverage, expected to add $2M annual revenue over a 10-year period | Slightly Positive — shows effort to add revenue, though it also makes the business story look less focused | --- ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | 29.1% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | -516.03% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | -153.25% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | ↑ | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | EPS Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Earnings Trend Interpretation:** There isn't enough earnings history in the provided dataset to judge whether management is consistently beating or missing expectations. That itself matters: when coverage is thin, the stock often trades more on sentiment and liquidity than on clean earnings signals. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 0 firms | 0% | | Hold | 0 firms | 0% | | Sell | 0 firms | 0% | **Target Price:** [Data unavailable] ~ [Data unavailable] (Median [Data unavailable]) **vs Current Price:** [Data unavailable] **Insider Activity:** Net [Data unavailable] in past 3 months > No analyst recommendation or insider transaction data was provided. In practice, that usually means institutional attention is limited, which is common for very small-cap speculative names. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Trading Volatility Risk:** Beta is 3.54 and the stock saw multiple circuit-breaker halts → If this continues, price can move violently in either direction regardless of business progress. 2. **Business Model Risk:** Net margin of -516.03% and operating margin of -512.69% show the core operation is not working economically → If losses persist, dilution or restructuring becomes more likely. 3. **Capital Markets Risk:** The reverse split suggests exchange/listing or price-maintenance pressure → If the stock weakens again after the split, shareholder dilution or further credibility damage could follow. --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** Akanda is a very small, speculative pharma-linked company whose stock currently trades more like a volatile micro-cap situation than a stable operating business. > > **Key strength:** The company has shown strong top-line growth and does not appear heavily burdened by long-term debt. > > **Key risk:** The biggest issue is that losses are enormous relative to revenue, and the recent reverse split plus trading halts make this look high-risk even by small-cap standards. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis